Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
|Articles|January 11, 2022
- Pharmaceutical Executive-01-01-2022
- Volume 42
- Issue 1
Our View on 2022: Pharm Exec’s Annual Industry Outlook
Advertisement
Articles in this issue
almost 5 years ago
Keeping Tabs on Quality: The Rise of Digitalalmost 5 years ago
China Invests in Building Biotechalmost 5 years ago
Branding Takes on a New Lookalmost 5 years ago
Addressing Access Burdensalmost 5 years ago
Meeting the Patient—Virtuallyalmost 5 years ago
The Age of Influencealmost 5 years ago
Boosting Immunotherapiesalmost 5 years ago
Pharma’s Psychedelic Experiencealmost 5 years ago
Supply Chain Procurementalmost 5 years ago
Breaking New Ground in BiopharmaAdvertisement
Related to this article
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5